A surprisingly potent nucleoside analogue

Torres, G.

Gmhc Treatment Issues the Gay Men's Health Crisis Newsletter of Experimental Aids Therapies 10(2): 8

1996


ISSN/ISBN: 1077-1824
PMID: 11363384
Document Number: 465618
Glaxo-Wellcome is developing a nucleoside analogue, 1529U89. The analogue shows potent in vitro activity against HIV, and initial tests of in-vivo efficacy are encouraging. The primary side effects of 1529U89 were nausea, headache, rash, and elevated liver function tests. Since the drug penetrates the central nervous system, participants are asked to allow spinal tips to measure the concentration of the drug in spinal fluid. Trials are being developed for 1529U89's use in AIDS-related dementia, and trials are being designed to test its effectiveness in combination with AZT and 3TC.

Document emailed within 1 workday
Secure & encrypted payments